185 related articles for article (PubMed ID: 20665806)
1. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH
Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.
Goto M; Hoxha N; Osman R; Wen J; Wells RG; Dell KM
J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910
[TBL] [Abstract][Full Text] [Related]
4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.
Shimomura Y; Brock WJ; Ito Y; Morishita K
Int J Toxicol; 2015; 34(6):479-90. PubMed ID: 26503599
[TBL] [Abstract][Full Text] [Related]
6. Modulation of P2X
Xu B; Nikolaienko O; Levchenko V; Choubey AS; Isaeva E; Staruschenko A; Palygin O
Physiol Rep; 2022 Nov; 10(21):e15510. PubMed ID: 36353932
[TBL] [Abstract][Full Text] [Related]
7. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
8. Role of genetic modifiers in an orthologous rat model of ARPKD.
O'Meara CC; Hoffman M; Sweeney WE; Tsaih SW; Xiao B; Jacob HJ; Avner ED; Moreno C
Physiol Genomics; 2012 Aug; 44(15):741-53. PubMed ID: 22669842
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
Jiang L; Fang P; Septer S; Apte U; Pritchard MT
Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868
[TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA
NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869
[TBL] [Abstract][Full Text] [Related]
11. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
[TBL] [Abstract][Full Text] [Related]
12. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.
Park F; Sweeney WE; Jia G; Akbulut T; Mueller B; Falck JR; Birudaraju S; Roman RJ; Avner ED
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F575-82. PubMed ID: 19129252
[TBL] [Abstract][Full Text] [Related]
13. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease.
Muff MA; Masyuk TV; Stroope AJ; Huang BQ; Splinter PL; Lee SO; Larusso NF
Lab Invest; 2006 Sep; 86(9):940-50. PubMed ID: 16783394
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
[TBL] [Abstract][Full Text] [Related]
16. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.
Masyuk TV; Huang BQ; Masyuk AI; Ritman EL; Torres VE; Wang X; Harris PC; Larusso NF
Am J Pathol; 2004 Nov; 165(5):1719-30. PubMed ID: 15509540
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
[TBL] [Abstract][Full Text] [Related]
20. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease.
Goto M; Hoxha N; Osman R; Dell KM
Pediatr Nephrol; 2010 Dec; 25(12):2449-57. PubMed ID: 20798958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
